Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × pazopanib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2 Gynecologic 2 CNS 1

Conditions

Glioblastoma 6 Gliosarcoma 3 Brain Neoplasms 3 Sarcoma 2 Melanoma 2 Glioma 2 Gastrointestinal Neoplasms 2 Central Nervous System Neoplasms 2 Breast Neoplasms 2 Wilms Tumor 1 Uterine Cervical Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Pheochromocytoma 1 Paraganglioma, Extra-Adrenal 1 Paraganglioma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Optic Nerve Glioma 1 Neuroblastoma 1 Neoplasms 1 Hypertension 1 Head and Neck Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 23 Bevacizumab 18 Cyclophosphamide 9 Carboplatin 7 Lomustine 6 Irinotecan 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 5 Filgrastim 5 Radiosurgery 4 Nivolumab 4 Everolimus 4 Etoposide 4 Busulfan 4 sonidegib 3 pembrolizumab 3 olaparib 3 fludarabine phosphate 3 fludarabine 3 antineoplaston AS 2-1 3 antineoplaston A10 3 Vincristine 3 Thiotepa 3 Sirolimus 3 Melphalan 3 IL13-PE38 3 Drug Therapy 3 Antilymphocyte Serum 3 verubulin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00350727 2013-04-19

VEG102857

GlaxoSmithKline

Phase 2 Completed

75 enrolled 45 charts

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡